Sai Life Sciences Limited is an innovator-focused contract research, development, and manufacturing organization (CRDMO) that provides end-to-end services across the drug discovery, development, and manufacturing value chain. It supports small molecule new chemical entities (NCEs) for global pharmaceutical and biotechnology firms. The company offers both contract research (CRO) and contract development and manufacturing (CDMO) capabilities.

Sai Life Sciences is one of the fastest-growing Indian CRDMOs in terms of revenue and EBITDA growth from FY 2022 to FY 2024. It serves over 280 pharmaceutical companies globally, including 18 of the top 25 pharmaceutical firms, with a significant presence in regulated markets like the US, UK, Europe, and Japan.

The company operates with research labs in innovation hubs like Greater Boston, US, and Manchester, UK, along with large-scale manufacturing facilities in India. This combination of global reach and cost-effective Indian operations allows Sai Life Sciences to support customers at various stages of the drug discovery-to-commercialization process.

Sai Life Sciences provides integrated CRO services in biology, chemistry, and drug metabolism, and has contributed to the approval of drugs and IND filings. In the CDMO space, it develops and manufactures active pharmaceutical ingredients (APIs) and intermediates for both clinical and commercial phases, including for blockbuster drugs.

The company has a diversified portfolio of over 170 innovator pharmaceutical products, including late-phase and early-phase drugs. It serves a broad customer base, with no single customer accounting for more than 8% of revenue. Its manufacturing facilities are accredited by global regulatory agencies, such as the USFDA and PMDA, Japan.

Sai Life Sciences is committed to sustainability, with initiatives aimed at energy conservation, increased use of renewable energy, and environmental protection. It has received a silver sustainability rating from EcoVadis and is a member of the Pharmaceutical Supply Chain Initiative (PSCI).

The company is led by an experienced management team, supported by investors like TPG Asia and HBM Private Equity India, and has a strong focus on corporate governance and environmental, social, and governance (ESG) strategies. As of September 2024, it employs over 3,100 staff, including a large team of scientists and engineers.